KAIST DEVELOPED LIGHTWEIGHT WEARABLE ROBOT FOR PARAPLEGIC USERS
Researchers at the Korea Advanced Institute of Science and Technology (KAIST) have developed a lightweight wearable robot, the WalkON Suit F1, designed to help paraplegic users walk, maneuver obstacles, and climb stairs. The robot, which weighs 50 kg (110 lb) and is powered by 12 electronic motors, uses sensors and cameras to monitor the user’s movements and surroundings, enabling seamless integration into daily life. The exoskeleton can lock itself onto users, allowing them to walk at a speed of 3.2 kph (2 mph) and even take sideways steps. Kim Seung-hwan, a paraplegic member of the team, demonstrated the prototype, emphasizing its unique ability to approach users and help them stand. Inspired by the movie “Iron Man,” the team aimed to create a functional assistive robot. Kim won a gold medal at Cybathlon 2024 wearing the suit, sharing his experience with his son and showcasing its potential for real-world applications. (Reuters)
SLOW RESPONSE TO MPox OUTBREAK IN DEMOCRATIC REPUBLIC OF CONGO
Mireille Efonge, a woman in Kinshasa, Democratic Republic of Congo, was diagnosed with mpox after developing painful blisters and fever. Her condition worsened until she was finally transported to a health center. In August, when mpox was largely unknown in Kinshasa, a new, rapidly spreading strain was identified in a remote town, leading the World Health Organization to declare it a global health emergency. The virus has since spread to displaced populations and cities like Kinshasa. Despite international donations of vaccines, the response has been slow and marred by bureaucracy, with vaccines sitting unused and limited contact tracing. Pakadjuma, a high-risk neighborhood, is a hotspot for two strains of mpox, affecting marginalized communities, especially sex workers. With increasing cases, including children infected by mothers, the response remains inadequate. Experts believe the outbreak could have been controlled earlier with timely international support and better infrastructure. (New York Times)
US COMPANIES TO BEGIN CLINICAL TRIALS OF XENOTRANSPLANTATION
Two U.S. companies plan to begin clinical trials of xenotransplantation in 2025, using genetically modified pig organs, such as kidneys and hearts, to address the shortage of human transplant organs. Patients like Alex Berrios, who faces a highly sensitized immune response, are eager to volunteer for the trials despite the risks, after seeing limited success in early experiments. In late 2023, Towana Looney became the fifth American to receive a pig kidney transplant at NYU, showing promising results after previous failed attempts. While initial xenotransplant recipients survived only briefly, the trials demonstrated that pig organs could function temporarily, revealing valuable lessons. The research focuses on gene editing, with varying approaches, to improve compatibility and reduce rejection. However, the transplants still have much to prove, and rigorous studies will be needed to assess their long-term potential. Researchers are balancing participant selection, hoping to find patients sick enough to qualify but healthy enough to benefit. (AP)
STEM CELL TRIAL OFFERS HOPE FOR PARKINSON’S TREATMENT
In 2024, Andrew Cassy, diagnosed with Parkinson’s disease in 2010, participated in a groundbreaking stem cell trial in Lund, Sweden. Surgeons transplanted neurons derived from human embryonic stem (ES) cells into his brain, aiming to replace damaged tissue. This trial is part of over 100 global studies exploring stem cells for treating diseases like Parkinson’s, diabetes, and heart failure. Stem-cell research has advanced significantly since the 1980s, with trials now using ES and induced pluripotent stem (iPS) cells to regenerate tissues. Parkinson’s disease is a key focus, with some trials showing promising results without the side effects of previous treatments. However, challenges remain, including finding the right cell types, overcoming immune rejection, and avoiding long-term immunosuppressants. While progress is slower for other organs, some stem-cell therapies for cancer and diabetes have shown significant potential. Cassy, undeterred by uncertainty, is hopeful his participation will contribute to future breakthroughs. (Nature)
NIH AND DOE ANNOUNCE PLANS FOR OPEN SCIENCE POLICY
In response to President Biden’s call for immediate free access to federally funded research, the NIH and DOE have released final plans to comply with the new open science policy. Starting by the end of 2025, researchers must post peer-reviewed manuscripts in public repositories immediately upon publication. While this policy aims to advance open access, universities and publishers have expressed concerns over logistics, costs, and revenue loss. Some support the “gold open access” model, where authors pay fees for immediate access, while others favor “green open access,” which allows for no-embargo public access but with fewer formatting and editing requirements. The policies have sparked debate, particularly around the impact on small nonprofit scientific societies and the challenges of educating researchers about non-APC alternatives. Additionally, publishers worry that this could undermine subscription fees and affect copyright control. Despite political uncertainty, experts predict the widespread adoption of zero-embargo green access. (Science)
OPENAI UNVEILS NEW AI REASONING MODELS O3 AND O3-MINI
On Day 12 of OpenAI’s “12 Days of OpenAI” event, CEO Sam Altman introduced the company’s new AI “reasoning” models, o3 and o3-mini, which improve upon the earlier o1 models. These models feature “private chain of thought,” a form of simulated reasoning (SR) that pauses for internal dialogue before responding, advancing beyond traditional large language models (LLMs). Although not yet publicly available, they will be accessible to safety researchers today. The o3 model earned record-breaking scores, including 87.5% on high-compute ARC-AGI benchmarks, comparable to human performance. It also scored 96.7% on the 2024 American Invitational Mathematics Exam. The o3-mini variant offers adaptive thinking times and outperforms o1 on the Codeforces benchmark. OpenAI’s move aligns with other companies like Google and DeepSeek exploring SR models, which fine-tune iterative reasoning processes. OpenAI plans to release o3-mini in January and o3 soon after. (Ars Technica)
FORMER OPENAI ENGINEER SUCHIR BALAJI DIES AT 26
Suchir Balaji, a former OpenAI engineer, has died at the age of 26. Balaji, who had worked at OpenAI for nearly four years, was a key contributor to the development of ChatGPT and other AI systems. He was found dead in his San Francisco apartment on November 26, with the cause of death ruled as suicide. Balaji had raised concerns about copyright infringement related to AI training data, especially after seeing lawsuits from authors and publishers against OpenAI. His disillusionment with the company grew over time, particularly due to issues with AI’s commercialization and internal conflicts. Balaji had been vocal about his concerns with OpenAI’s practices and had planned to testify in ongoing copyright cases. Colleagues at OpenAI praised his contributions and described him as an exceptional engineer. His family continues to seek answers, and a memorial is planned in California. (AP)
Thanks for reading. Let’s be careful out there.
WORDS: The Biology Guy.